Presentation is loading. Please wait.

Presentation is loading. Please wait.

MicroRNA Expression Profiling of Esophageal Cancer Before and After Induction Chemoradiotherapy  Michael Augustine Ko, MD, PhD, Guan Zehong, MS, Carl.

Published byPhebe Neal Modified over 6 years ago

Similar presentations

Presentation on theme: "MicroRNA Expression Profiling of Esophageal Cancer Before and After Induction Chemoradiotherapy  Michael Augustine Ko, MD, PhD, Guan Zehong, MS, Carl."— Presentation transcript:

1 MicroRNA Expression Profiling of Esophageal Cancer Before and After Induction Chemoradiotherapy 
Michael Augustine Ko, MD, PhD, Guan Zehong, MS, Carl Virtanen, MS, Maha Guindi, MD, Thomas K. Waddell, MD, PhD, Shaf Keshavjee, MD, MS, Gail E. Darling, MD  The Annals of Thoracic Surgery  Volume 94, Issue 4, Pages (October 2012) DOI: /j.athoracsur Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Experimental design. (miRNA = microRNA; pCR = pathologic complete response.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 (A) Unsupervised hierarchical cluster analysis using full gene set of 1,536 miRNA sequences extracted from preoperative biopsy specimens. Inset shows detail from main heat map. Each column represents a sample; categorical variable is pathologic complete response (pCR), listed at bottom of inset. (B) Supervised hierarchical cluster analysis using 71 genes whose expression was significantly altered between pCR and non-pCR preoperative biopsy specimens. Categorical variable is pCR, listed at bottom of inset. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 (A) Unsupervised hierarchical cluster analysis using full gene set of 1,536 miRNA sequences extracted from postoperative surgical specimens. Inset demonstrates detail from main heat map. Each column represents a sample; categorical variable is pathologic complete response (pCR), listed at bottom of inset. (B) Supervised hierarchical cluster analysis using 52 genes whose expression was significantly altered between pCR and non-pCR specimens. Categorical variable is pCR, listed at bottom of inset. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 (A) Unsupervised hierarchical cluster analysis using full gene set of 1,536 miRNA sequences extracted from preoperative and postoperative specimens. Inset demonstrates detail from main heat map. Each column represents a sample; categorical variable is pretreatment and posttreatment, listed at bottom of inset. (B) Supervised hierarchical cluster analysis using 568 genes whose expression was significantly altered between pretreatment and posttreatment specimens. Categorical variable is pretreatment and posttreatment, listed at bottom of inset. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

6 Fig 5 (A) Overall survival for entire 25-patient cohort. Curve generated by method of Kaplan-Meier. (B) Overall disease-free survival (DFS). (C) DFS stratified by pCR. Trend toward improved DFS in pCR group (p = 0.19). (D) DFS stratified by miR-145 expression. Improved survival in the low miR-145 expression group (n = 8; p = 0.04). (E) DFS stratified by miR-135b expression. Improved survival in the high miR-135b expression group (n = 8; p = 0.04). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "MicroRNA Expression Profiling of Esophageal Cancer Before and After Induction Chemoradiotherapy  Michael Augustine Ko, MD, PhD, Guan Zehong, MS, Carl."

Similar presentations

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E
Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi.

Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi.
High Risk of Prosthetic Valve Endocarditis and Death After Valve Replacement Operations in Dialysis Patients  Danielle K. Farrington, MD, Patrick D. Kilgo,

High Risk of Prosthetic Valve Endocarditis and Death After Valve Replacement Operations in Dialysis Patients  Danielle K. Farrington, MD, Patrick D. Kilgo,
Elizabeth A. David, MD, David T

Elizabeth A. David, MD, David T
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,

Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Late Vascular Complications After Extracorporeal Membrane Oxygenation Support  Daniel Zimpfer, MD, Birgit Heinisch, MD, Martin Czerny, MD, Thomas Hoelzenbein,

Late Vascular Complications After Extracorporeal Membrane Oxygenation Support  Daniel Zimpfer, MD, Birgit Heinisch, MD, Martin Czerny, MD, Thomas Hoelzenbein,
Association of Perioperative Fluid Balance and Adverse Surgical Outcomes in Esophageal Cancer and Esophagogastric Junction Cancer  Shenhai Wei, MD, PhD,

Association of Perioperative Fluid Balance and Adverse Surgical Outcomes in Esophageal Cancer and Esophagogastric Junction Cancer  Shenhai Wei, MD, PhD,
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E

Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E
Phillips B. Harrington, MD, William W. McAlexander, MD, Ayesha S

Phillips B. Harrington, MD, William W. McAlexander, MD, Ayesha S
Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B
Invasive Mediastinal Staging Guideline Concordance

Invasive Mediastinal Staging Guideline Concordance
Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer  Lars P. Riber, MD, PhD, Thomas D. Christensen,

Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer  Lars P. Riber, MD, PhD, Thomas D. Christensen,
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma  Jeeyun Lee, MD, Kyoung-Eun.

Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma  Jeeyun Lee, MD, Kyoung-Eun.
Long-Term Outcome After Resection of Non-Small Cell Lung Cancer Invading the Thoracic Inlet  Stéphane Collaud, MD, MS, Tiago Machuca, MD, PhD, Olaf Mercier,

Long-Term Outcome After Resection of Non-Small Cell Lung Cancer Invading the Thoracic Inlet  Stéphane Collaud, MD, MS, Tiago Machuca, MD, PhD, Olaf Mercier,
Dhaval Chauhan, MD, Alexis K

Dhaval Chauhan, MD, Alexis K
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Similar presentations

Ads by Google